EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Klinische Studie (Phase II)Open Access · CC BY 4.0

Pooled safety analysis of lurbinectedin plus irinotecan in patients with advanced solid tumors

Alejandro Falcón, Gregory M Cote, Javier Molina-Cerrillo, Axel Le Cesne, Pedro Rocha, Bruno Bockorny, David Paez, Javier Martin-Broto, Sant P Chawla, Sara Martinez, Carmen Kahatt, Vicente Alfaro und 8 weitere

Investigational New Drugs · 2026-06 · 44 (3) · 274-283

DOI: 10.1007/s10637-026-01616-0 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Investigational New Drugs, online erschienen am 04.05.2026. Verfasst von Alejandro Falcón und 19 weiteren Autor:innen. Beteiligte Einrichtung: Medical Oncology Department, Hospital Universitario Virgen del Rocio, Seville, Spain. afalconglez@gmail.com. Hauptthemen laut MEDLINE: Irinotecan, Antineoplastic Combined Chemotherapy Protocols, Heterocyclic Compounds, 4 or More Rings, Carbolines. Die Arbeit nennt 13 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: PharmaMar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Lurbinectedin in combination with irinotecan showed synergistic antitumor activity in preclinical studies. A phase I/II trial (NCT02611024) evaluated this combination in patients with advanced solid tumors. The phase II stage evaluated the antitumor activity of the recommended dose (RD) (lurbinectedin 2.0 mg/m 2 on Day (D)1 plus irinotecan 75 mg/m 2 on D1 and D8 q3wk with primary granulocyte colony-stimulating factor prophylaxis) in five tumor-specific cohorts. This pooled analysis describes the safety profile of this combination from 233 patients with different advanced solid tumors treated at the RD. Adverse events (AEs) and laboratory abnormalities were graded using NCI-CTCAE v.4. The most frequent AEs (any grade) related to treatment were fatigue (71% of patients/25% of cycles), diarrhea (62%/17%), nausea (59%/18%), vomiting (35%/7%) and decreased appetite (32%/6%); the most common grade ≥ 3 AEs were fatigue (14%/2%), diarrhea (14%/2%) and febrile neutropenia (9%/1%). The most common grade ≥ 3 laboratory abnormality regardless of relationship was neutropenia (53%). The rate of discontinuation due to treatment-related AEs was 3% ( n = 7 patients). There was one treatment-related death (0.4%) involving a 63-year-old male patient (0.4%) diagnosed with metastatic NEN who died due to grade 5 staphylococcal bacteremia. In conclusion, this pooled analysis shows a predictable and manageable safety profile for lurbinectedin in combination with irinotecan in patients with advanced solid tumors, with myelosuppression, fatigue and gastrointestinal disorders being the main toxicities observed. Trial code: ClinicalTrials.gov identifier: NCT02611024.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

IrinotecanAntineoplastic Combined Chemotherapy ProtocolsHeterocyclic Compounds, 4 or More RingsCarbolinesNeoplasmsHumansMaleMiddle AgedAgedFemaleAdultYoung AdultAged, 80 and over

Stichwörter der Autor:innen

IrinotecanLurbinectedinPhase IPhase IIPooled safety

Substanzen

IrinotecanPM 01183Heterocyclic Compounds, 4 or More RingsCarbolines

Autor:innen und Institutionen

  • Medical Oncology Department, Hospital Universitario Virgen del Rocio, Seville, Spain. afalconglez@gmail.com.
  • Servicio de Oncología Médica, Hospital Universitario Virgen del Rocio, Avenida Manuel Siurot, S/N, 41013, Seville, Spain. afalconglez@gmail.com.
  • Medical Oncology Department, Mass General Brigham Cancer Institute, Boston, MA, USA.
  • Medical Oncology Department, Hospital Universitario Ramón y Cajal, Madrid, Spain.
  • Medical Oncology Department, Institute Gustave Roussy, Villejuif, France.
  • Medical Oncology Department, Vall d' Hebrón University Hospital, Barcelona, Spain.

Förderung

  • PharmaMar

Zitieren

APA

Falcón, A., Cote, G. M., Molina-Cerrillo, J., Le Cesne, A., Rocha, P., Bockorny, B., Paez, D., Martin-Broto, J., Chawla, S. P., Martinez, S., Kahatt, C., Alfaro, V., Siguero, M., Jimenez, J., Custodio, A., Alonso-Orduña, V., López, C., Kollár, A., Soto-Castillo, J. J., & Paz-Ares, L. (2026). Pooled safety analysis of lurbinectedin plus irinotecan in patients with advanced solid tumors. Investigational New Drugs, 44(3), 274-283. https://doi.org/10.1007/s10637-026-01616-0

Vancouver

Falcón A, Cote GM, Molina-Cerrillo J, Le Cesne A, Rocha P, Bockorny B, et al. Pooled safety analysis of lurbinectedin plus irinotecan in patients with advanced solid tumors. Investigational New Drugs. 2026;44(3):274-283. doi:10.1007/s10637-026-01616-0

BibTeX
@article{Falcn2026,
  author = {Falcón, Alejandro and Cote, Gregory M and Molina-Cerrillo, Javier and Le Cesne, Axel and Rocha, Pedro and Bockorny, Bruno and Paez, David and Martin-Broto, Javier and Chawla, Sant P and Martinez, Sara and Kahatt, Carmen and Alfaro, Vicente and Siguero, Mariano and Jimenez, Javier and Custodio, Ana and Alonso-Orduña, Vicente and López, Carlos and Kollár, Attila and Soto-Castillo, Juan José and Paz-Ares, Luis},
  title = {Pooled safety analysis of lurbinectedin plus irinotecan in patients with advanced solid tumors},
  journal = {Investigational New Drugs},
  year = {2026},
  volume = {44},
  number = {3},
  pages = {274--283},
  doi = {10.1007/s10637-026-01616-0}
}
Kostenlos starten →